1-3 of 3
John M. Nicoll, BS
Close
Sort by
Journal Articles

Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors.

Neil P. Shah, MD, PhD, Brian Skaggs, PhD, Susan Branford, BS, Timothy P. Hughes, MD, John M. Nicoll, BS, Ronald L. Paquette, MD, Charles L. Sawyers, MD
Journal: Blood
Blood (2006) 108 (11): 751.
https://doi.org/10.1182/blood.V108.11.751.751
Published: 2006
Journal Articles

Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development.

Neil P. Shah, MD, PhD, John M. Nicoll, BS, Eric Bleickardt, MD, Claude Nicaise, MD, Ronald L. Paquette, MD, Charles L. Sawyers, MD
Journal: Blood
Blood (2006) 108 (11): 2166.
https://doi.org/10.1182/blood.V108.11.2166.2166
Published: 2006
Journal Articles

The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy.

Neil P. Shah, MD, PhD, Brian Skaggs, PhD, Susan Branford, BS, Timothy P. Hughes, MD, John M. Nicoll, BS, Ronald L. Paquette, MD, Charles L. Sawyers, MD
Journal: Blood
Blood (2006) 108 (11): 2175.
https://doi.org/10.1182/blood.V108.11.2175.2175
Published: 2006